Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

Last updated: April 11, 2023
Sponsor: Dong-A ST Co., Ltd.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Turner Syndrome

Severe Short Stature

Hormone Deficiencies

Treatment

N/A

Clinical Study ID

NCT04798690
DA3002_SS_OS
  • Ages > 2
  • All Genders

Study Summary

This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Children with short stature by growth hormone deficiency(GHD) or idiopathic shortstature (ISS) or turner's syndrome(TS) or small for gestational age(SGA)
  • Children who has official height record at least 6 months prior

Exclusion

Exclusion Criteria:

  • Children with Epiphyseal closure

Study Design

Total Participants: 2500
Study Start date:
February 08, 2021
Estimated Completion Date:
December 31, 2031

Connect with a study center

  • Yonsei University Health System, Severance Hospital

    Seoul, Seodaemun-gu 03722
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.